Subscribe to Search results

At a UKHCDO meeting a potential trial of prophylactic treatment was discussed and it was stated that they would only be able to undertake the trial at the Lord Mayor Treloar College.

Published on:

It was suggested that trials were possible at Treloar's due to the fact that the boys were under close daily observation for prolonged periods.

Published on:

The protocol for the Double-blind Controlled Trial of Prophylactic treatment at Treloars stated that half the children would only get a low dose in order for the trial to be effective.

Published on:

A proposal was submitted for a trial of prophylactic administration of cryoprecipitate at Treloars.

Published on:

Dr Aronstam sought a clinical trial exemption certificate to permit him to administer Mono-V3:C, a product of Speywood Laboratories, to 50 pupils over a period of 8 months.

Published on:

The Committee on Safety of Medicines advised that the bulk cryoprecipitate was to be prepared by Alpha Therapeutic only from source plasma derived from their own licensed plasmapheresis centres. This was considered to be risky as the effects resulting from these products were uncertain.

Published on:

Due to a large research grant Treloar's was able to supply students with much more blood product than their home clinicians.

Published on:

At a time of growing concerns about concentrates manufactured in the USA from large pools, no cryoprecipitate was used at Treloar's in 1982.

Published on:

At a time of growing concerns about concentrates manufactured in the USA from large pools, no cryoprecipitate was used at Treloar's in 1983.

Published on:

Treloar's were able to arrange to keep a pupil on one type of treatment for the 1975 hepatitis study.

Published on:

It was acknowledged there was a risk that the hepatitis might be Hepatitis B, even though screening had improved since RIA testing.

Published on:

It was stated that there were a variety of responses to exposure to hepatitis B virus in human beings: acute hepatitis, asymptomatic infection with little or no liver damage, chronic hepatitis, persistent production of hepatitis B viral antigen and antibody to surface antigens.

Published on:

Alter et al showed that after excluding commercial and Hepatitis B antigen positive donors, post-transfusion hepatitis remained.

Published on:

Dr Rainsford identified that the hepatitis of a boy under his care at Treloar's was almost certainly caused by plasma.

Published on:

There was a hepatitis outbreak at Treloar's in 1975.

Published on:

Dr Arblaster asked a parent of a Treloar's student to reconsider their decision to withdraw consent for him to be treated with "new material".

Published on:

The results of a third prophylaxis trial undertaken at Treloar's were reported to UKHCDO Directors.

Published on:

A trial was carried out at Treloar's aimed to see if prophylaxis would improve the radiological appearance of joints and "more particularly have any influence on haemophilic cysts." It was stated that there could be a significant lessening in the number of bleeds, but to achieve this, it would require amounts of concentrate which were simply unavailable in such quantities.

Published on:

Andrew Quinn, a pupil at Treloar's, was selected to receive Factor 8 prophylactically for a year. He was never advised that there were any risks attached to receiving Factor 8.

Published on:

From 1970 to 1973, Dr Rainsford studied the incidence of serum hepatitis. The aim was to see if there was any pattern to the way in which antibodies and antigens to serum hepatitis correlated with clinical illness, the frequency of transfusion and the presence of antigens in the blood products with which they were being treated.

Published on: